(CCCC) C4 Therapeutics - Overview

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US12529R1077

Stock:

Total Rating 30
Risk 31
Buy Signal 2.18
Biotechnology +3.0
Biotechnology +1.8
Market Cap: 232m
Avg Trading Vol: 2.03M USD
ATR: 7.14%
Peers RS (IBD): 44.50
Risk 5d forecast
Volatility 120%
Relative Tail Risk -17.8%
Reward TTM
Sharpe Ratio 0.44
Alpha -39.87
Character TTM
Beta 2.372
Beta Downside 2.817
Drawdowns 3y
Max DD 90.00%
CAGR/Max DD -0.20

EPS (Earnings per Share)

EPS (Earnings per Share) of CCCC over the last years for every Quarter: "2020-12": -0.04, "2021-03": -0.49, "2021-06": -0.51, "2021-09": -0.51, "2021-12": -0.31, "2022-03": -0.65, "2022-06": -0.56, "2022-09": -0.65, "2022-12": -0.77, "2023-03": -0.71, "2023-06": -0.73, "2023-09": -0.52, "2023-12": -0.7, "2024-03": -0.41, "2024-06": -0.26, "2024-09": -0.35, "2024-12": -0.49, "2025-03": -0.37, "2025-06": -0.37, "2025-09": -0.44, "2025-12": 0,
EPS CAGR: 52.04%
EPS Trend: 76.2%
Last SUE: 4.00
Qual. Beats: 1

Revenue

Revenue of CCCC over the last years for every Quarter: 2020-12: 8.262, 2021-03: 7.426, 2021-06: 9.781, 2021-09: 8.5, 2021-12: 20.078, 2022-03: 7.654, 2022-06: 13.834, 2022-09: 6.754, 2022-12: 2.854, 2023-03: 3.759, 2023-06: 2.664, 2023-09: 11.072, 2023-12: 3.261, 2024-03: 3.039, 2024-06: 12.006, 2024-09: 15.362, 2024-12: 5.177, 2025-03: 7.238, 2025-06: 6.463, 2025-09: 11.23, 2025-12: null,
Rev. CAGR: -14.35%
Rev. Trend: 1.3%
Last SUE: 0.97
Qual. Beats: 1

Description: CCCC C4 Therapeutics

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 clinical trials targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting BRAF V600 mutant that is in Phase 1/2 clinical trials to treat melanoma, colorectal cancer, and other solid malignancies; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor with an L858R mutation in non-small cell lung cancer. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; Merck KGaA; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Piotroski VR‑10 (Strict, 0-10) 1.0

Net Income: -119.1m TTM > 0 and > 6% of Revenue
FCF/TA: -0.36 > 0.02 and ΔFCF/TA -16.78 > 1.0
NWC/Revenue: 567.7% < 20% (prev 682.9%; Δ -115.3% < -1%)
CFO/TA -0.36 > 3% & CFO -94.5m > Net Income -119.1m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 5.76 > 1.5 & < 3
Outstanding Shares: last quarter (72.6m) vs 12m ago 4.22% < -2%
Gross Margin: 80.53% > 18% (prev 0.77%; Δ 7976 % > 0.5%)
Asset Turnover: 9.39% > 50% (prev 8.95%; Δ 0.43% > 0%)
Interest Coverage Ratio: -23.35 > 6 (EBITDA TTM -121.0m / Interest Expense TTM -5.32m)

Altman Z'' -13.99

A: 0.64 (Total Current Assets 206.9m - Total Current Liabilities 35.9m) / Total Assets 265.5m
B: -2.71 (Retained Earnings -718.2m / Total Assets 265.5m)
C: -0.39 (EBIT TTM -124.3m / Avg Total Assets 320.8m)
D: -6.46 (Book Value of Equity -718.1m / Total Liabilities 111.1m)
Altman-Z'' Score: -13.99 = D

Beneish M -3.81

DSRI: 0.71 (Receivables 6.54m/10.3m, Revenue 30.1m/33.7m)
GMI: 0.95 (GM 80.53% / 76.78%)
AQI: 0.44 (AQ_t 0.04 / AQ_t-1 0.10)
SGI: 0.89 (Revenue 30.1m / 33.7m)
TATA: -0.09 (NI -119.1m - CFO -94.5m) / TA 265.5m)
Beneish M-Score: -3.81 (Cap -4..+1) = AAA

What is the price of CCCC shares?

As of February 26, 2026, the stock is trading at USD 2.77 with a total of 6,518,261 shares traded.
Over the past week, the price has changed by +45.03%, over one month by +33.82%, over three months by +11.69% and over the past year by -0.72%.

Is CCCC a buy, sell or hold?

C4 Therapeutics has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy CCCC.
  • StrongBuy: 4
  • Buy: 0
  • Hold: 4
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the CCCC price?

Issuer Target Up/Down from current
Wallstreet Target Price 11.3 307.6%
Analysts Target Price 11.3 307.6%

CCCC Fundamental Data Overview February 26, 2026

P/S = 7.6932
P/B = 1.5064
Revenue TTM = 30.1m USD
EBIT TTM = -124.3m USD
EBITDA TTM = -121.0m USD
Long Term Debt = 61.5m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 6.22m USD (from shortTermDebt, last quarter)
Debt = 61.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.65m USD (from netDebt column, last quarter)
Enterprise Value = 101.2m USD (231.6m + Debt 61.5m - CCE 191.9m)
Interest Coverage Ratio = -23.35 (Ebit TTM -124.3m / Interest Expense TTM -5.32m)
EV/FCF = -1.06x (Enterprise Value 101.2m / FCF TTM -95.1m)
FCF Yield = -93.94% (FCF TTM -95.1m / Enterprise Value 101.2m)
FCF Margin = -315.8% (FCF TTM -95.1m / Revenue TTM 30.1m)
Net Margin = -395.5% (Net Income TTM -119.1m / Revenue TTM 30.1m)
Gross Margin = 80.53% ((Revenue TTM 30.1m - Cost of Revenue TTM 5.86m) / Revenue TTM)
Gross Margin QoQ = none% (prev 67.75%)
Tobins Q-Ratio = 0.38 (Enterprise Value 101.2m / Total Assets 265.5m)
Interest Expense / Debt = -8.66% (Interest Expense -5.32m / Debt 61.5m)
Taxrate = 21.0% (US default 21%)
NOPAT = -98.2m (EBIT -124.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.76 (Total Current Assets 206.9m / Total Current Liabilities 35.9m)
Debt / Equity = 0.40 (Debt 61.5m / totalStockholderEquity, last quarter 154.4m)
Debt / EBITDA = -0.02 (negative EBITDA) (Net Debt 2.65m / EBITDA -121.0m)
Debt / FCF = -0.03 (negative FCF - burning cash) (Net Debt 2.65m / FCF TTM -95.1m)
Total Stockholder Equity = 184.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -37.12% (Net Income -119.1m / Total Assets 265.5m)
RoE = -64.40% (Net Income TTM -119.1m / Total Stockholder Equity 184.9m)
RoCE = -50.44% (EBIT -124.3m / Capital Employed (Equity 184.9m + L.T.Debt 61.5m))
RoIC = -53.10% (negative operating profit) (NOPAT -98.2m / Invested Capital 184.9m)
WACC = 11.59% (E(231.6m)/V(293.1m) * Re(14.66%) + (debt cost/tax rate unavailable))
Discount Rate = 14.66% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 19.03%
[DCF] Fair Price = unknown (Cash Flow -95.1m)
EPS Correlation: 76.19 | EPS CAGR: 52.04% | SUE: 4.0 | # QB: 1
Revenue Correlation: 1.32 | Revenue CAGR: -14.35% | SUE: 0.97 | # QB: 1
EPS next Quarter (2026-03-31): EPS=-0.31 | Chg7d=+0.000 | Chg30d=+0.000 | Revisions Net=+0 | Analysts=2
EPS next Year (2026-12-31): EPS=-1.29 | Chg7d=+0.000 | Chg30d=+0.000 | Revisions Net=+0 | Growth EPS=+15.3% | Growth Revenue=-28.9%

Additional Sources for CCCC Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Fund Manager Positions: Dataroma | Stockcircle